Vol 63, No 4 (2012)
Review paper
Submitted: 2013-02-15
Published online: 2012-08-30
Hypothyroidism during treatment with tyrosine kinase inhibitors
Aneta L. Zygulska, Krzysztof Krzemieniecki, Anna Sowa-Staszczak
DOI: 10.5603/ep.25164
·
Endokrynol Pol 2012;63(4):302-306.
Vol 63, No 4 (2012)
Review Article
Submitted: 2013-02-15
Published online: 2012-08-30
Abstract
Tyrosine kinase inhibitors are relatively new targeted therapy drugs used for the treatment of metastatic clear cell kidney carcinoma, gastrointestinal
stromal tumours, thyroid carcinoma and pancreatic neuroendocrine tumours during the progression of the disease. Hypothyroidism
or thyroid dysfunction is often a side effect of this treatment. Therefore, monitoring of thyroid hormone levels before the beginning
and during the treatment of tyrosine kinase inhibitors is a necessity. Hypothyroidism correlates with objective response to the treatment.
Sunitinib. This is the most described tyrosine kinase inhibitor which causes hypothyroidism. The mechanism of hypothyroidism is still unclear.
Sorafenib. Symptoms of hypothyroidism occur in 18% of patients treated with sorafenib due to metastatic renal cell carcinoma.
Imatinib. Hypothyroidism is one of the most frequent side effects of the treatment. Emergent tracheotomy was necessary due to larynx
swelling during marked hypothyroidism.
Motesanib. Hypothyroidism or increased TSH level is diagnosed in 22% to 69% of patients with metastatic differentiated or medullary
thyroid carcinomas. The management of patients with thyroid dysfunction and related symptoms such as fatigue is undoubtedly a challenge
to an oncologist.
Abstract
Tyrosine kinase inhibitors are relatively new targeted therapy drugs used for the treatment of metastatic clear cell kidney carcinoma, gastrointestinal
stromal tumours, thyroid carcinoma and pancreatic neuroendocrine tumours during the progression of the disease. Hypothyroidism
or thyroid dysfunction is often a side effect of this treatment. Therefore, monitoring of thyroid hormone levels before the beginning
and during the treatment of tyrosine kinase inhibitors is a necessity. Hypothyroidism correlates with objective response to the treatment.
Sunitinib. This is the most described tyrosine kinase inhibitor which causes hypothyroidism. The mechanism of hypothyroidism is still unclear.
Sorafenib. Symptoms of hypothyroidism occur in 18% of patients treated with sorafenib due to metastatic renal cell carcinoma.
Imatinib. Hypothyroidism is one of the most frequent side effects of the treatment. Emergent tracheotomy was necessary due to larynx
swelling during marked hypothyroidism.
Motesanib. Hypothyroidism or increased TSH level is diagnosed in 22% to 69% of patients with metastatic differentiated or medullary
thyroid carcinomas. The management of patients with thyroid dysfunction and related symptoms such as fatigue is undoubtedly a challenge
to an oncologist.
Keywords
hypothyroidism; tyrosine kinase inhibitors
Title
Hypothyroidism during treatment with tyrosine kinase inhibitors
Journal
Endokrynologia Polska
Issue
Vol 63, No 4 (2012)
Article type
Review paper
Pages
302-306
Published online
2012-08-30
Page views
732
Article views/downloads
2326
DOI
10.5603/ep.25164
Bibliographic record
Endokrynol Pol 2012;63(4):302-306.
Keywords
hypothyroidism
tyrosine kinase inhibitors
Authors
Aneta L. Zygulska
Krzysztof Krzemieniecki
Anna Sowa-Staszczak
About this article
